Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11709391 | 0.89 | TSHR (0.44) | DHODHALDH1A1GAAMEN1KMT2A | |
| SCHEMBL5767408 | 0.87 | KEAP1 (0.42) | DHODHALDH1A1GAARXFP1MEN1 | |
| SCHEMBL440033 | 0.83 | KEAP1 (0.49) | DHODHALDH1A1GAARXFP1MEN1 | |
| SCHEMBL22395713 | 0.83 | DHODH (0.46) | DHODHALDH1A1GAARXFP1MEN1 | |
| SCHEMBL7496024 | 0.83 | DHODH (0.46) | DHODHALDH1A1GAARXFP1MEN1 | |
| SCHEMBL1618188 | 0.81 | PARP1 (0.41) | ALDH1A1MEN1KMT2AMAPTTHRB | |
| SCHEMBL741418 | 0.81 | HTT (0.55) | DHODHALDH1A1GAARXFP1MEN1 | |
| SCHEMBL12786944 | 0.81 | ALDH1A1 (0.49) | DHODHALDH1A1GAAMEN1KMT2A | |
| SCHEMBL30819200 | 0.81 | ALDH1A1 (0.49) | DHODHALDH1A1GAAMEN1KMT2A | |
| SCHEMBL12850079 | 0.81 | HSD17B10 (0.41) | ALDH1A1MEN1KMT2AMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304712-A | Preparation method of modified barium sulfate powder, modified barium sulfate powder and application thereof | 青岛红蝶新材料有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | claimed |
| CN-117304712-B | Preparation method of modified barium sulfate powder, modified barium sulfate powder and application thereof | 青岛红蝶新材料有限公司 | 2026-02-06 | — | — | CN | disclosed |
| CN-117304712-A | Preparation method of modified barium sulfate powder, modified barium sulfate powder and application thereof | 青岛红蝶新材料有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117304712-A | Preparation method of modified barium sulfate powder, modified barium sulfate powder and application thereof | 青岛红蝶新材料有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-107501099-B | Modulators of ATP-binding cassette transporters | 沃泰克斯药物股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-26 | — | — | US | disclosed |
| CN-111162313-A | Polymer electrolyte and lithium ion battery | 珠海冠宇电池有限公司 | 2020-05-15 | — | — | CN | disclosed |
| EP-3216787-B1 | INTERMEDIATES FOR THE PREPARATION OF MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-16 | — | — | US | disclosed |
| EP-1687276-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-04-06 | — | — | US | disclosed |
| WO-2006002421-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | AVENTIS PHARMA S.A. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005049575-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2005-06-02 | — | — | WO | disclosed |
| CN-85106626-A | The preparation of 4-amino-2-phenyl-quinoline | — | 1987-03-25 | — | — | CN | disclosed |
| US-4588731-A | Derivatives of isoxazolo[4,5-c]quinoline(2H)-3-one and method of preparation and use as anxiolytic agents | ROUSSEL UCLAF (FR) | 1986-05-13 | — | — | US | disclosed |
| EP-0168812-A1 | 4-Amino-2-phenyl quinolines, methods and intermediates for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-01-22 | — | — | EP | disclosed |
| US-4560692-A | ANTICONVULSANTS OR ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144450-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | DHODH 2093/4885ALDH1A1 2165/4885GAA 454/4885 |
| US-10662192-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | DHODH 2093/4885ALDH1A1 2165/4885GAA 454/4885 |
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | QRFPR, NQO2, DHX35 | DHODH 533/4885ALDH1A1 2137/4885GAA 3830/4885 |
| US-20060074075-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders | CFTR, ABCC4, ABCC2 | DHODH 2931/4885ALDH1A1 2221/4885GAA 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.